Replies to post #150410 on Biotech Values

[mcbio]

RCPT - MS play going public

http://www.receptos.com/pdfs/Receptos_S-1_filing_pressrelease.pdf

Seems that there's a consensus regarding BG-12 becoming the biggest drug in MS in time. Aubagio doesn't look like a great choice considering its limited efficacy and tox and certainly not a 1st line drug. Alemtuzumab's safety issues will very much limit its use.
No mention of Gilenya just next gen S1P1 compounds?

Curious how hot of an MS target S1P1 is right now. Also, you referenced next gen S1P1 drugs. What are the first gen S1P1 drugs and who are the other competitors in the next gen space besides RCPT?